Human medicines European public assessment report (EPAR): Toujeo (previously Optisulin), insulin glargine, Diabetes Mellitus, Date of authorisation: 26/06/2000, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Talvey, talquetamab, Multiple Myeloma, Date of authorisation: 21/08/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Voxzogo, vosoritide, Achondroplasia, Date of authorisation: 26/08/2021, Revision: 4, Status: Authorised

Azamethiphos (extension to fin fish): European public maximum-residue-limit assessment report (EPMAR)

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, Online, from 19/09/2023 to 20/09/2023

Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 6-9 November 2023

List of medicines currently in PRIME scheme

Awareness session for SMEs on the reform of the EU pharmaceutical legislation, Online, 10:00 – 12:00 (Amsterdam time CET), from 24/11/2023 to 24/11/2023

Human medicines European public assessment report (EPAR): Herwenda, trastuzumab, Breast Neoplasms;Stomach Neoplasms, Date of authorisation: 15/11/2023, Status: Authorised

Regulatory acceptance of 3R (replacement, reduction, refinement) testing approaches - Scientific guideline